The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin

BJU International

Volumn 118, Issue 1, 2016, Pages 44-52

  Gontero, Paolo ^a   Sylvester, Richard ^b   Pisano, Francesca ^a   Joniau, Steven ^c   Oderda, Marco ^a   Serretta, Vincenzo ^d   Larré, Stéphane ^e   Di Stasi, Savino ^f   Van Rhijn, Bas ^g   Witjes, Alfred J ^h   Grotenhuis, Anne J ^h   Colombo, Renzo ⁱ   Briganti, Alberto ⁱ   Babjuk, Marek ^j   Soukup, Viktor ^j   Malmström, Per Uno ^k   Irani, Jacques ^l   Malats, Nuria ^m   Baniel, Jack ⁿ   Mano, Roy ⁿ   Cai, Tommaso ^o   Cha, Eugene K ^p   Ardelt, Peter ^q   Vakarakis, John ^r   Bartoletti, Riccardo ^s   Dalbagni, Guido ^t   Shariat, Shahrokh F ^p   Xylinas, Evanguelos ^p   Karnes, Robert J ^u   Palou, Joan ^v   more..

^a UNIVERSITY OF TURIN   (Italy)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^g ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^j UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^k UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^l POITIERS UNIVERSITY HOSPITAL   (France)

^m Structural Biology and Biocomputing Programme   (Spain)

ⁿ RABIN MEDICAL CENTER   (Israel)

^o SANTA CHIARA HOSPITAL   (Italy)

^p WEILL CORNELL MEDICAL COLLEGE   (United States)

^q UNIVERSITY OF FREIBURG   (Germany)

^r UNIVERSITY OF ATHENS   (Greece)

^s UNIVERSITY OF FLORENCE   (Italy)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^u MAYO CLINIC   (United States)

^v UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

bladder cancer; high grade; progression; re TUR; recurrence; T1G3

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETRUSOR MUSCLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 84975122035     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13354     Document Type: Article

References (18)

1. Babjuk M, Burger M, Zigeuner R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013; 64: 639–53
2. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 62–7
3. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006; 97: 1194–8
4. Herr HW. Role of re-resection in non-muscle-invasive bladder cancer. ScientificWorldJournal 2011; 11: 283–8
5. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162: 74–6
6. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314–30
7. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010; 58: 185–90
8. Angulo JC, Palou J, García-Tello A, de Fata FR, Rodríguez O, Villavicencio H. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin. Actas Urol Esp 2014; 38: 164–71
9. Mack D, Höltl W, Bassi P et al. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol 2001; 165: 401–3
10. Shindo T, Masumori N, Kitamura H et al. Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC). World J Urol 2014;32:1281–5.
11. Svatek RS, Hollenbeck BK, Holmäng S et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014;66:253–62.
12. Gontero P, Sylvester R, Pisano F et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol 2015; 67: 74–82
13. Sfakianos JP, Shariat SF, Favaretto RL, Rioja J, Herr HW. Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int 2011; 108: 526–30
14. Fritsche HM, Burger M, Svatek RS et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010; 57: 300–9
15. Ritch CR, Clark PE, Morgan TM. Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how? Urol Clin North Am 2013; 40: 295–304
16. Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001; 166: 490–3
17. Hemdan T, Johansson R, Jahnson S, Hellström P, Tasdemir I, Malmström PU; Members of the Urothelial Cancer Group of the Nordic Association of Urology. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer. J Urol 2014; 191: 1244–9
18. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964–70